newsfilter
← Latest News
GlobeNewswire·

SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)

ICU
  • SeaStar Medical Holding Corporation announced it is a sponsor of the KidneyBee Summit 2026 at Children's Hospital Colorado from July 14 to 16, 2026, to advance treatment for pediatric acute kidney injury (AKI).
  • The company will host an educational webinar on August 11, 2026, from 12:00 to 1:00 p.m. ET titled "Rethinking Pediatric Sepsis-Associated AKI: What Clinicians Should Know About QUELIMMUNE."
  • The webinar will feature speakers including Dr. Stuart Goldstein, Dr. Stephen Gorga, Katie Plomaritas, Theresa Mottes, and SeaStar Medical CMO Dr. Kevin Chung.
  • The event focuses on QUELIMMUNE (SCD-PED) therapy, a first-in-class device approved in February 2024 that neutralizes over-active immune cells to stop cytokine storms in pediatric patients weighing 10 kilograms or more.
  • Clinical trial data published in Kidney Medicine showed a 77% survival rate for patients treated with QUELIMMUNE versus standard of care, representing a 50% reduction in mortality compared to historical data.
  • Real-world data from the QUELIMMUNE SAVE Registry involving 21 pediatric patients showed a 76% survival rate at Day 60 with no device-related adverse events or infections.
  • SeaStar Medical received the 2025 Corporate Innovator Award from the National Kidney Foundation for the approval of the QUELIMMUNE therapy.
  • The Selective Cytopheretic Device (SCD) therapy is integrated with existing renal replacement therapy systems to target proinflammatory monocytes without requiring pathogen removal.
  • SeaStar Medical is currently conducting the NEUTRALIZE-AKI pivotal clinical trial for adult patients with AKI requiring continuous renal replacement therapy.
  • The company holds Breakthrough Device Designation from the FDA for six therapeutic indications related to its SCD therapy.